(AOF) – Theradiag announces a net result of 853,000 euros in the first half, compared to a net loss of 56,000 euros a year ago. The in vitro diagnostics specialist posted a turnover up 7% to 6.7 million euros and an operating profit of 835,000 euros, with an operating margin of 12.5%. As of June 30, 2023, Theradiag’s net available cash amounted to 5.7 million euros, a level higher than the company’s business plan and increasing during the second quarter of 2023, compared to 6.4 million euros. euros as of December 31, 2022.
Theradiag attributes these good results in particular to the progression of products with higher margins in its turnover, including mainly the growth in the share of autoimmunity within IVD and in the share of sales of tests in within Theranostics. The company also cites the receipt of milestone payments from Quotient following the strategic partnership and the optimization of the management of operational expenses mainly due to the cessation of activities in the United States.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
